


Click [here](#) if you are having trouble viewing this message.



May newsletter

Spotlight on: Clinical adoption

The UK [ATTC Network](#) is a world-first system of Advanced Therapy Treatment Centres (ATTCs), operating within the NHS framework and coordinated by CGT Catapult, that is addressing the unique and complex challenges of bringing pioneering advanced therapies to patients. The project has been funded by the Industrial Strategy Challenge Fund, part of the government's modern Industrial Strategy, and was set up in March 2018. In its first year, the network has already achieved many successes.

Midlands and Wales Advanced Therapy Treatment Centre ([MW-ATTC](#)) have:

- Generated standard of care clinical patient process maps for autologous and allogenic ATMPs.
- Developed a data structure and accompanying user interface which will support allogeneic therapies.

Northern Alliance Advanced Therapies Treatment Centre ([NA-ATTC](#)) have:

- Held their first major dissemination event to share knowledge on delivery of Advanced Therapies in the NHS, with a particular focus on CAR T-cell therapies.
- Alongside partner Leeds Teaching Hospital, applied significant clinical trials experience with oncolytic virus in the delivery of a new commissioned service for T-VEC; the first licensed gene therapy approved for use at this hospital.

Innovate Manchester Advanced Therapy Centre Hub ([iMATCH](#)) have:

- Finalised the protocol for the Immetacyte sponsored exemplar trial, OvStar, which is due for submission to the MHRA imminently.

- Opened enrolment at the University of Manchester for the first [Masters of Science \(MSc\) degree](#) in Advanced Therapy Medicinal Products (ATMPs).

Read more of the network's achievements on the [ATTC Network website](#).

The network had a joint presence at the recent [World Advanced Therapies and Regenerative Medicine Congress](#), where clinical adoption was a key topic. CGT Catapult's Dr Jacqueline Barry hosted a two panel discussions on the challenges of adoption with contributors including ATTC members Karen Hodgkin, COO, Cell Medica; Neil Watson, Director, NA-ATTC; Dr Ian McKay, Innovation Lead for Advanced Therapies, Innovate UK; and Marc Turner, Co-Director, NA-ATTC.



Did you visit the ATTC Network stand at the **World Advance Therapies and Regenerative Medicine Congress?**

Share this email on social media




News



Developing analytics for high throughput quality control

£2.9m funding from the Hertfordshire Local Enterprise Partnership will support the delivery of new analytical technologies, overcoming a barrier to industry expansion and facilitating the growth and delivery scale required for adoption of personalised medicines.

[Read the press release](#)



Nobel Prize-winning researcher, Professor Shinya Yamanaka, visits CGT Catapult

Professor Yamanaka and colleagues from the Center for iPS Cell Research and Application (CiRA) visited CGT Catapult to share collective experience in the development of iPS cells for clinical applications and to take a tour of the CGT Catapult development laboratories and manufacturing centre.

[See photos of the visit](#)

Meet us at these upcoming events

ISCT 2019 Annual Meeting

Melbourne, Australia

29 May - 01 June 2019

We are attending ISCT 2019 in collaboration with the UK's National Institute for Health and Care Excellence (NICE) to meet cell and gene therapy experts with an interest in the UK ATMP ecosystem.

Chief Clinical Officer Dr Jacqueline Barry will be co-chairing a joint session with ISCT: Global

Pricing & Reimbursement Strategies, Friday 31st May, 10:45-12:15.

We also hosted the Industry Networking reception at the Crowne Metropole Hotel on 30 May where Chief Executive Officer Keith Thompson said a few words.

[Sign up to receive our monthly newsletter](#)

Contact us

+44 (0) 203 728 9500

12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT



The Cell and Gene Therapy Catapult takes your data very seriously, you can read how we may use it in our [privacy policy](#). If you no longer want to hear from us [unsubscribe here](#).